Schering Corporation

Merck Sharp + Dohme Corp.

Jeffrey F Lowrie

Andrew William Stamford

Jared N Cumming

Tao Guo

Ying Huang

Corey Strickland

Ulrich Iserloh

Yusheng Wu

Douglas Walsh Hobbs

Johannes H Voigt

Thuy X H Le

Samuel Chackalamannil

Yan Xia

Suresh D Babu

Kurt William Saionz

Guoqing Li

Jianping Pan

Disclosed are compounds of the formula or a pharmaceutically acceptable salt or solvate thereof, wherein  and the remaining variables are as defined in the specification. Also disclosed are pharmaceutical compositions comprising the compounds of formula I. Also disclosed are methods of treating cognitive or neurodegenerative diseases such as Alzheimer's disease. Also disclosed are pharmaceutical compositions and methods of treating cognitive or neurodegenerative diseases comprising the compounds of formula I in combination with a &#x3b2;-secretase inhibitor other than those of formula I, an HMG-CoA reductase inhibitor, a gamma-secretase inhibitor, a non-steroidal anti-inflammatory agent, an N-methyl-D-aspartate receptor antagonist, a cholinesterase inhibitor or an anti-amyloid antibody.

Cyclic amine BACE-1 inhibitors having a benzamide substituent

Disclosed are novel compounds of the formula or a pharmaceutically acceptable salt or solvate thereof, wherein  Also disclosed are pharmaceutical compositions comprising the compounds of formula I and methods of treating cognitive or neurodegenerative diseases with compounds of formula I. Also disclosed are pharmaceutical compositions and methods of treatment comprising compounds of formula I in combination with other agents useful in treating cognitive or neurodegenerative diseases.

Cyclic amine BACE-1 inhibitors having a heterocyclic substituent

Growing community of inventors

Pennington, NJ, United States of America

Jeffrey F Lowrie